Amgen Presents New Data For IMDELLTRA In Small Cell Lung Cancer At WCLC 2024; DeLLphi-303 Study Results Show Potential For IMDELLTRA In Combination With A PD-L1 Inhibitor As First-Line Maintenance Therapy In ES-SCLC
Amgen Presents New Data For IMDELLTRA In Small Cell Lung Cancer At WCLC 2024; DeLLphi-303 Study Results Show Potential For IMDELLTRA In Combination With A PD-L1 Inhibitor As First-Line Maintenance Therapy In ES-SCLC
DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC
Dellphi-303 研究结果显示，IMDELLTRA 与 PD-L1 抑制剂联合用作 ES-SCLC 的一线维持疗法的潜力
DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA
Dellphi-301 长期随访数据显示 IMDELLTRA 持续的安全性和有效性
THOUSAND OAKS, Calif., Sept. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE) molecule, at the 2024 World Conference on Lung Cancer (WCLC) in San Diego.
加利福尼亚州千橡市，2024年9月9日 /PRNewswire/ — 安进（纳斯达克股票代码：AMGN）今天宣布在2024年世界肺癌大会（WCLC）上公布了新数据，该数据显示了同类首创的靶向双特异性T细胞Engager（BiTE）分子的同类首创的靶向三角洲样配体（DLL3）（BiTE）在圣地亚哥。
IMDELLTRA will be featured in two oral presentations at the "DLL3 Targeting BiTE Therapies in SCLC" session, taking place today at 2:00 p.m. PDT. New data from the global Phase 1b DeLLphi-303 study of IMDELLTRA combined with PD-L1 inhibitors in first-line maintenance extensive-stage small cell lung cancer (ES-SCLC) will be presented as a late-breaking abstract (#LBA OA10.04). Additionally, long-term results from the Phase 2 DeLLphi-301 study in previously treated ES-SCLC will be highlighted as an oral presentation (#OA10.03).
IMDELLTRA将在太平洋夏令时间今天下午2点举行的 “SCLC中的DL3靶向BiTE疗法” 会议上发表两场口头演讲。关于IMDELLTRA 与 PD-L1 抑制剂联合治疗一线维持广泛期小细胞肺癌（ES-SCLC）的全球第10期DellPhi-303期研究的新数据将作为最新摘要（#LBA OA10.04）公布。此外，对先前接受过治疗的ES-SCLC的2期DellPHI-301研究的长期结果将以口头陈述的形式重点介绍（#OA10 .03）。